• Immunohistochemistry analysis of paraffin-embedded human brain tissue, using SOX9 Antibody. The picture on the right is blocked with the synthesized peptide.
  • Western blot analysis of lysates from 293 cells, treated with PBS 60', using SOX9 Antibody. The lane on the right is blocked with the synthesized peptide.
  • Western blot analysis of various cells using Sox-9 Polyclonal Antibody diluted at 1：2000 cells nucleus extracted by Minute TM Cytoplasmic and Nuclear Fractionation kit (SC-003, Inventbiotech, MN, USA).
  • Immunofluorescence analysis of A549 cells, using SOX9 Antibody. The picture on the right is blocked with the synthesized peptide.
  • Immunofluorescence analysis of rat-spleen tissue. 1, Sox-9 Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
  • Immunofluorescence analysis of rat-spleen tissue. 1, Sox-9 Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
  • Immunofluorescence analysis of rat-lung tissue. 1, Sox-9 Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
  • Immunofluorescence analysis of rat-lung tissue. 1, Sox-9 Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
  • Immunofluorescence analysis of Hela cell. 1, Sox-9 Polyclonal Antibody (red) was diluted at 1:200 (4°C overnight). Alpha-tubulin monoclonal antibody (8F11) (green) was diluted at 1:200 (4°C overnight). 2, Goat Anti Rabbit Alexa Fluor 594 Catalog: (NA was diluted at 1:1000 (room temperature, 50min). Goat Anti Mouse Alexa Fluor 488 Catalog: (NA was diluted at 1:1000 (room temperature, 50min).

Anti-SOX9 antibody (147-196 aa) (STJ95736)

SKU:
STJ95736

£46.00 - £226.00
Current Stock:
Host: Rabbit
Applications: WB/IHC/IF/ELISA
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Transcription factor SOX-9 (147-196 aa) is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence and ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-1:2000
IHC 1:100-1:300
IF 1:200-1:1000
ELISA 1:5000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: SOX9
Gene ID: 6662
Uniprot ID: SOX9_HUMAN
Immunogen Region: 147-196 aa
Specificity: Sox-9 Polyclonal Antibody detects endogenous levels of Sox-9 protein.
Immunogen: The antiserum was produced against synthesized peptide derived from the human SOX9 at the amino acid range 147-196
Function Transcription factor that plays a key role in chondrocytes differentiation and skeletal development. Specifically binds the 5'-ACAAAG-3' DNA motif present in enhancers and super-enhancers and promotes expression of genes important for chondrogenesis, including cartilage matrix protein-coding genes COL2A1, COL4A2, COL9A1, COL11A2 and ACAN, SOX5 and SOX6. Also binds to some promoter regions. Plays a central role in successive steps of chondrocyte differentiation. Absolutely required for precartilaginous condensation, the first step in chondrogenesis during which skeletal progenitors differentiate into prechondrocytes. Together with SOX5 and SOX6, required for overt chondrogenesis when condensed prechondrocytes differentiate into early stage chondrocytes, the second step in chondrogenesis. Later, required to direct hypertrophic maturation and block osteoblast differentiation of growth plate chondrocytes: maintains chondrocyte columnar proliferation, delays prehypertrophy and then prevents osteoblastic differentiation of chondrocytes by lowering beta-catenin (CTNNB1) signaling and RUNX2 expression. Also required for chondrocyte hypertrophy, both indirectly, by keeping the lineage fate of chondrocytes, and directly, by remaining present in upper hypertrophic cells and transactivating COL10A1 along with MEF2C. Low lipid levels are the main nutritional determinant for chondrogenic commitment of skeletal progenitor cells: when lipids levels are low, FOXO (FOXO1 and FOXO3) transcription factors promote expression of SOX9, which induces chondrogenic commitment and suppresses fatty acid oxidation. Mechanistically, helps, but is not required, to remove epigenetic signatures of transcriptional repression and deposit active promoter and enhancer marks at chondrocyte-specific genes. Acts in cooperation with the Hedgehog pathway-dependent GLI (GLI1 and GLI3) transcription factors. In addition to cartilage development, also acts as a regulator of proliferation and differentiation in epithelial stem/progenitor cells: involved in the lung epithelium during branching morphogenesis, by balancing proliferation and differentiation and regulating the extracellular matrix. Controls epithelial branching during kidney development.
Protein Name Transcription Factor Sox-9
Database Links Reactome: R-HSA-3769402
Reactome: R-HSA-8878166
Reactome: R-HSA-9690406
Cellular Localisation Nucleus
Alternative Antibody Names Anti-Transcription Factor Sox-9 antibody
Anti-SOX9 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance